Altimmune Announces $75 Million Registered Direct Equity Offering

Altimmune ( (ALT) ) has shared an announcement.

On January 27, 2026, Altimmune, Inc. entered into a Securities Purchase Agreement with a new fundamental institutional investor for a registered direct offering of 12,397,920 shares of common stock and pre-funded warrants to purchase up to 4,647,534 additional shares, with closing expected on or about January 29, 2026, subject to customary conditions. The deal, arranged with Titan Partners Group as sole placement agent, is expected to raise approximately $75 million in gross proceeds, includes 30-day lock-up agreements for directors and executives, and features non-expiring pre-funded warrants with ownership caps, underscoring the company’s continued reliance on equity financing while imposing short-term trading restrictions on insiders.

The most recent analyst rating on (ALT) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Altimmune stock, see the ALT Stock Forecast page.

Spark’s Take on ALT Stock

According to Spark, TipRanks’ AI Analyst, ALT is a Neutral.

The score is held down primarily by very weak financial performance (severe losses and negative cash flow), partially offset by strong clinical/regulatory progress highlighted in the earnings call and recent Phase 2b MASH results. Technically, the trend is positive but appears overbought, and valuation is constrained by loss-making fundamentals and no dividend data.

To see Spark’s full report on ALT stock, click here.

More about Altimmune

Altimmune, Inc. is a biopharmaceutical company that issues common stock and related securities to fund its operations, targeting institutional investors through registered offerings in the U.S. capital markets.

Average Trading Volume: 4,668,145

Technical Sentiment Signal: Buy

Current Market Cap: $590.6M

For an in-depth examination of ALT stock, go to TipRanks’ Overview page.